Citations

Citations to this article as recorded by  

• Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy
  Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua
  Epilepsia.2026; 67(3): 1246.     CrossRef
• Engineered exosomal delivery of semaglutide activates SIRT1–FOXO3a–miR-124 signaling and protects against cortical neuroinflammation
  Elsayed A. Elmorsy, Sameh Saber, Ahmed Y. Kira, Manal Mohamed Hatem, Mohammed Alorini, Suzan Awad AbdelGhany Morsy, Hamad Alsaykhan, Abdulaziz A. Alsalloom, Nahla B. Mohamed, Norah Suliman Alsoqih, Rabab S. Hamad, Youssef El-Sayed, Nagwa Mahmoud Ramadan,
  Journal of Drug Delivery Science and Technology.2026; 118: 108078.     CrossRef
• Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations
  Nimet Yılmaz, Mehmet Bastemir
  Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists and Acute Pancreatitis: Current Evidence and Clinical Implications
  Kwang Hyun Chung, Jaihwan Kim
  The Korean Journal of Pancreas and Biliary Tract.2026; 31(1): 1.     CrossRef
• Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review
  Claudia Reytor-González, Martín Campuzano-Donoso, Gerardo Sarno, Martha Montalvan, Raquel Horowitz, Gianluca Rossetti, Vincenzo Pilone, Luigi Barrea, Giovanna Muscogiuri, Luigi Schiavo, Daniel Simancas-Racines
  Nutrients.2026; 18(4): 553.     CrossRef
• Oral Administration of Crocus sativus Tepals Extract Restores High‐Fat Diet‐Induced Gut Dysbiosis and Modulates Intestinal Inflammation and Hepatic Lipid Metabolism
  Biljana Bursać, Miloš Vratarić, Ljupka Gligorovska, Luisa Bellachioma, Ana Teofilović, Danijela Vojnović Milutinović, Camilla Morresi, Elisabetta Damiani, Tiziana Bacchetti, Ana Djordjevic
  BioFactors.2026;[Epub]     CrossRef
• A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis
  Suhasini Rallabandi, Mansi Sharma, Krishnamraju Kosuru, Rahul Kashyap
  Cureus.2026;[Epub]     CrossRef
• The pancreatic signal of GLP‐1 receptor agonists: A biliary phenomenon rather than direct toxicity
  Andro Koren, Luciana Koren
  British Journal of Clinical Pharmacology.2026;[Epub]     CrossRef
• Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
  Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan
  Chronic Diseases and Translational Medicine.2026; 12(2): 100.     CrossRef
• Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE)
  Antonio Facciorusso, Edoardo G Giannini, Matteo Tacelli, Alberto Zanetto, Cristiano Spada, Ivo Boskoski, Manuele Furnari, Grazia Pennisi, Gabriele Capurso, Alessandro Vitello, Giovanni Marasco, Giovanni Sarnelli, Luca Frulloni, Marcello Maida
  Digestive and Liver Disease.2026; 58(6): 737.     CrossRef
• Adverse effects of GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directions
  Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Chiamaka Linda Mgbechidinma, Wafaa Ramadan Ahmed
  Obesity Medicine.2026; 61: 100699.     CrossRef
• New generation anti-obesity drugs and bone health in postmenopausal women
  Jana Tomasová Studýnková
  Vnitřní lékařství.2026; 72(2): 104.     CrossRef
• Re-establishing alliances: “Old Friends” confronting obesity, inflammation, and stress-related psychiatric disorders
  Luke W. Desmond, Christopher A. Lowry
  Brain Behavior and Immunity Integrative.2026; 15: 100166.     CrossRef
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Limosilactobacillus fermentum K8-Lb1 Postbiotic on Weight Management and Metabolic Health Outcomes
  Ekaterina Papazova, Susanne Mitschke, Christiane Laue, Jürgen Schrezenmeir
  Nutrients.2026; 18(8): 1174.     CrossRef
• Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review
  Uchechukwu Bethel Abioke, Isaac Baiden, Obiageri Ihuarulam Okeoma, Victoria Partey-Newman, Temitope Oluwatosin Adewale, Shadrach Oluchi Onyekezini, Ijeoma Linda Okwuowulu
  Epidemiology and Health Data Insights.2026; 2(3): ehdi035.     CrossRef
• Assessment of knowledge, attitude, and practices towards the usage of antidiabetic drugs for weight loss among Lebanese population
  Dima Kreidieh, Rouba Ballout, Rana Abutaima, Samer A. Kharroubi, Fatima A. Saleh
  BMC Public Health.2026;[Epub]     CrossRef
• A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies
  Iman Saad Ahmed, Sara Luay Tapponi, Hala Malek Manaa, Amina Soltani, Elzahraa Shehata Hussein, Fatemeh Ali Parvaresh, Zahid Hussain, Jasbir Arora (RSS)
  Journal of Obesity.2026;[Epub]     CrossRef
• The case for primary prevention of obesity in the era of GLP-1 therapies
  Søren Holm, Manuel Tena-Sempere, Dimitrios Koutsouris, George V. Dedoussis, Karl-Heinz Wagner, Sara Arranz, Philippe Froguel, Torsten Bohn, Paulo J. Oliveira, Jeroen Lakerveld, Aakruti Kaikini, Achim Kramer, Adam Selamnia, Adina Weinberger, Adrian Jauch,
  The Lancet Regional Health - Europe.2026; 66: 101679.     CrossRef
• The neuro-metabolic epidemic and the CB1R paradox
  Francesca Vaccaro, Ginevra Malta, Manfredi Rizzo, Fulvio Plescia, Gianluca Lavanco
  Current Opinion in Pharmacology.2026; 89: 102631.     CrossRef
• Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis
  Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Wafaa Ramadan Ahmed, Khalid Hamid Fadul
  INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2026;[Epub]     CrossRef
• GIPR:GCGR co-agonism restores normal weight in obese rodents
  Diego Perez-Tilve, Fa Zhang, Yujin Zhang, Kaitlyn Lohman, Joyce Sorrell, Andrew Vick, Timo D. Müller, Matthias H. Tschöp, Richard D. DiMarchi
  Molecular Metabolism.2026; 108: 102365.     CrossRef
• Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulation
  Ying-Ru Chen, Zheng-Hong Jiang, Jui-Yi Chen, Vin-Cent Wu
  GeroScience.2026;[Epub]     CrossRef
• The Gastrointestinal Safety of Orforglipron, a GLP‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials
  Ahmed W. Hageen, Ahmed Farid Gadelmawla, Ahmad Omar Saleh, Abdallfatah Abdallfatah, Mohamed Reyad Mohamed, Amira Fahmy El‐Nemr, Odai Maihoub, Ahmed Elsekhary, Safir Eladawi, Biruk Demisse Ayalew, Ahmed Mansour, Ayoup Ahmed Radi, Mohamed Abuelazm, Mohamed
  Endocrinology, Diabetes & Metabolism.2026;[Epub]     CrossRef
• Tirzepatide versus Semaglutide: Selecting the Right Agent for the Right Patient in Contemporary Metabolic Care
  Ahmad Alam
  Bangladesh Journal of Endocrinology and Metabolism.2026;[Epub]     CrossRef
• Systematic Characterisation of GLP‐1R in Human Enteric Nervous System: Implications for GLP‐1 as a Key Regulator of Colonic Activity
  Kiran Devi Dontamsetti, Rubina Aktar, Madusha Peiris
  Journal of Neurochemistry.2026;[Epub]     CrossRef
• Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis
  Po-Lung Cheng, Hua-Ching Chang
  Diabetes Research and Clinical Practice.2026; 237: 113333.     CrossRef
• Unexpected Therapeutic Effect of GLP-1 Receptor Agonists in Patients With Refractory IBS-D: A Case Series
  Solangel Isabelle Suarez, Bilori Bilori, Sai Venkat Aluri, Saurav Das
  Annals of Internal Medicine: Clinical Cases.2026;[Epub]     CrossRef
• Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists
  Maria-Daniela Tanasescu, Andrei-Mihnea Rosu, Alexandru Minca, Maria-Mihaela Grigorie, Delia Timofte, Dorin Ionescu
  Life.2026; 16(5): 756.     CrossRef
• Microneedles (MNs)-based technology for diabetes management: design, delivery, and artificial intelligence integration
  Fuad Saleh, Zakarya A.M. Hazaea, Mansour Alantry Abdu, Waleed Alahmad, Mohammad Ashfaq
  Inorganic Chemistry Communications.2026; 190: 116931.     CrossRef
• Nutritional Care for Adults With Obesity Treated With Glucagon-Like Peptide (GLP)-1 and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications
  Cici McGuane, Nosha Farhadhar, Khavir A Sharieff, Stephanie N Petrosky, Karima Alabasi
  Cureus.2026;[Epub]     CrossRef
• New Avenues in Adjunctive Pharmacotherapy for Substance Use Disorders
  David Crockford, Anees Bahji
  Canadian Journal of Addiction.2026; 17(2): 4.     CrossRef
• Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance
  Raynier Zambrano-Villacres, Martín Campuzano-Donoso, Claudia Reytor-González, Gianluca Rossetti, Luigi Cobellis, Francesco Cobellis, Vincenzo Pilone, Daniel Simancas-Racines, Luigi Schiavo
  Nutrients.2026; 18(11): 1751.     CrossRef
• Obesity Management in Primary Care: Clinical Approaches and Policy Implications in the Era of Incretin-Based Therapies
  Chung-woo Lee
  Korean Journal of Family Practice.2026; 16(2): 81.     CrossRef
• GLP‐1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study
  Jisu Park, Ju Hwan Kim, Yoon Seob Kim, Gyeongmin Lim, Hong Ji Song, Sang Youl Rhee, Seonghoon Hwang, Daeun Cho, Minyoung Kim, Bo‐Yeon Kim, Chang Won Jeong, Dae‐Yeon Kim, Hang A Park, Min‐Ho Kim, Seong Hwan Kim, Won‐Woo Seo, Woo Jin Kim, Young Sung Suh, Ra
  Diabetes, Obesity and Metabolism.2026; 28(9): 8649.     CrossRef
• Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study
  Chungsoo Kim, Seonji Kim, Dong Yun Lee, Eugene Han, Yong‐ho Lee, Seng Chan You
  Diabetes, Obesity and Metabolism.2026; 28(9): 8482.     CrossRef
• Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care
  Paola Mogna-Peláez, Marta Guasch-Ferré
  The Journal of Nutrition.2026; 156(8): 101684.     CrossRef
• Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation
  Shashank R. Joshi, Anoop Misra, Ambrish Mithal, Banshi Saboo, Krishna G. Seshadri, Subhankar Chowdhury, Ganapathi Bantwal, Bipin Sethi, Jothydev Kesavadev, Arpan Dev Bhattacharya, Manash P. Baruah, Ajay Budhwar, Priti Thakor, Sachin Shende, Viswanathan Mo
  Obesity Pillars.2026; 19: 100296.     CrossRef
• Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies
  Edoardo Caimi, Emanuele Mark Ghetti, Federico Giovagnoli, Stefano Vaccari, Gianmaria Ceglia, Mattia Federico Cavallero, Roberta Comunian, Riccardo Di Giuli, Alessandra Veronesi, Francesco Klinger, Valeriano Vinci
  Aesthetic Plastic Surgery.2026; 50(17): 7549.     CrossRef
• Glucagon-like Peptide-1 Receptor Agonists and Chronic Pain: Preclinical Antinociceptive Mechanisms, Indirect Metabolic–Functional Effects, and Clinical Considerations—A Narrative Review
  Sung-woo Hyung, Ui Jin Park, Jeong Hwan Ryu, Siwook Chung
  Journal of Clinical Medicine.2026; 15(15): 5932.     CrossRef
• Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review
  Wah-Kheong Chan, Hak-Keith Leung, Guo-Jeng Tan, Quan-Hziung Lim, Lee-Ling Lim, Jeyakantha Ratnasingam, Shireene Ratna Vethakkan
  Journal of Obesity & Metabolic Syndrome.2026; 35(3): 298.     CrossRef
• Perceptions, attitudes, and experiences of GLP-1 receptor agonists for weight management in the United Kingdom: a cross-sectional survey study
  Jason Tallis, Darren Richardson, Michael J Duncan, Ricardo Martins, Thomas M Barber, Leigh Breen, Anna Higo, Helen M Jones, David R Broom
  BMC Public Health.2026;[Epub]     CrossRef
• Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes
  Artur Dziewierz, Natalia Kulicka, Krzysztof Łupina, Natalia Maruszak, Aleksandra Gałuszka, Justyna Domienik-Karłowicz, Anna Rulkiewicz, Zbigniew Siudak
  Diabetes Research and Clinical Practice.2026; 239: 113493.     CrossRef
• Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure
  Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab
  Otolaryngology–Head and Neck Surgery.2026;[Epub]     CrossRef
• Glucose-responsive probiotics for glycaemic modulation in mice and monkeys
  Ningzi Guan, Deqiang Kong, Xianyun Gao, Lingxue Niu, Yang Zhou, Guiling Yu, Tian Gao, Mengyao Liu, Wenbo Ma, Yiyu Jin, Jianli Yin, Shangang Zhao, Haifeng Ye
  Nature.2026; 657(8131): 477.     CrossRef
• GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals
  Alessandro Conforti, Carlos Cifuentes-González, Kajal Rupesh Agrawal, Rupesh Agrawal
  Drug Discovery Today.2026; 31(5): 104786.     CrossRef
• DIFFERENCES IN SAFETY PROFILE AND ADVERSE EFFECTS OF ORAL AND SUBCUTANEOUS GLP-1 ANALOGUES: A SYSTEMATIC REVIEW AND REAL-WORLD DATA ANALYSIS (2024–2026)
  Aleksandra Olga Pakulska, Natalia Rządzińska, Aleksandra Maria Błoch, Kornelia Julia Fimiarz, Aleksandra Katarzyna Kłosowicz, Maria Anna Miller, Aleksandra Jolanta Kamińska
  International Journal of Innovative Technologies in Social Science.2026;[Epub]     CrossRef
• Prospects for the use of new antidiabetic drugs in rheumatology
  E. L. Nasonov, M. V. Shestakova, L. V. Kondratyeva, M. S. Eliseev
  Rheumatology Science and Practice.2026; 64(4): 315.     CrossRef
• Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan
  Ioanna Panagiota Kalafati, David Krongauz, Alice Bosco, Antonio Noto, Cristina Piras, Maria Kafyra, Angelica Dessì, Matteo Mauri, Luigi Atzori, Adina Weinberger, Vassilios Fanos, George V. Dedoussis
  Obesity Reviews.2026;[Epub]     CrossRef
• Shifting the Paradigm in Global Diabetes Management: Beyond Glycohemoglobinism and Toward Etiological Mitigation via Minimizing Insulin Resistance on the Basis of Pharmacogenetics
  Sidhartha D. Ray, Lining Liang He, Stratton Rottersmann, Christina Hand, Maria Di Leo, Alec Chunilall, Ian G. Gray, Ngo Tsun Siu, Sonia Jong, Nigel Sirois, Kaitlin M. McNeely, Margarett A. Costes
  Diabetology.2026; 7(9): 176.     CrossRef
• Glucagon-like peptide-1 receptor agonists in dermatology: ethical considerations
  Chelsea Deitelzweig, Fatima Rahim, Benjamin K Stoff
  Clinics in Dermatology.2026;[Epub]     CrossRef
• Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
  Ji Yoon Kim, Nam Hoon Kim
  Diabetes & Metabolism Journal.2026; 50(5): 844.     CrossRef
• Incretin-based obesity management medications: Implications for clinical practice and future perspectives
  Sanja Klobučar, Andrej Belančić, Elvira Meni Maria Gkrinia, Tomislav Božek, Ida Štimac, Andreea Ciudin Mihai
  Best Practice & Research Clinical Gastroenterology.2026; : 102141.     CrossRef
• Type 2 diabetes mellitus: emerging mechanistic insights, evolving therapeutic strategies, and future perspectives
  Himanshu, Suryakant Verma, Sonam Yadav, Asmita Singh, Jaishiv Chauhan, Sameeksha, Kshitiz Sahu, Anup Kumar Mamgain
  Discover Endocrinology and Metabolism.2026;[Epub]     CrossRef
• Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report
  Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel
  Diabetes, Obesity and Metabolism.2026;[Epub]     CrossRef
• Long-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practice
  Davide Brancato, Giorgio Borretta, Marco Chianelli, Olga Disoteo, Marco Grasso, Franco Grimaldi, Edoardo Guastamacchia, Fabrizio Muratori, Salvatore Oleandri, Marcello Orio, Paola Pantanetti, Enrico Papini, Agnese Persichetti, Roberto Vettor, Federica Vin
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• Impact of Glucagon-Like Peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) Receptor Agonists on Intraocular Pressure in Glaucoma: A Case Series
  Coy Steel, Catherine Johnson, Chase Paulson, Jesse Terrell, Qi N Cui, Lauren Blieden, Barbara Wirostko
  Journal of Ophthalmology and Advance Research.2026; 7(3): 1.     CrossRef
• Benzothiazole-Derived Compounds as Potential Drugs for the Treatment of Type 2 Diabetes: A Descriptive Review
  Ana María Correa-Basurto, Miguel Valdes, Laura Cristina Cabrera-Pérez, Natalia Reyes Vallejo, Alejandro Cruz, Martha Cecilia Rosales-Hernández, Juan Andres Alvarado-Salazar, Jessica Elena Mendieta-Wejebe
  International Journal of Molecular Sciences.2026; 27(19): 8863.     CrossRef
• Beyond Weight Loss: Tolerability, Acceptability, and Patient-Centered Outcomes of GLP-1 Receptor Agonists in Polycystic Ovary Syndrome
  Urvah Tauseef, Farshi Farook, Vaishnavi J. Shetty, Edith Ramos-Ocola, Chandra Rupini Premkumar, Muhammad Zaryab Haider, Aashna Gandhi, Tunisha Shingala, Simardeep Singh, Muhammad Moiz Tahir, Sancia Mary Jerold Wilson, Kaaviyashri Saraboji, Jyoti Yadav, An
  Reproductive Medicine.2026; 7(4): 55.     CrossRef
• Response to comment on “Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials”
  Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam
  Sleep Medicine.2025; 134: 106709.     CrossRef
• Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
  Shikha Patel, Sarfaraz K. Niazi
  Pharmaceutics.2025; 17(8): 1036.     CrossRef
• GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective
  Pietro Carmellini, Alessandro Cuomo, Maria Beatrice Rescalli, Andrea Fagiolini
  Life.2025; 15(9): 1422.     CrossRef
• Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus
  Deyong Yue, Xuesheng Hua, Ling Zhu, Jun Wang, Lihua Gu, Zhengxia Yuan, Wenle Jian, Yirong Chen, Guoliang Meng
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
  Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
  Diabetes & Metabolism Journal.2025; 49(6): 1331.     CrossRef
• Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders
  Ralf Weiskirchen, Amedeo Lonardo
  Medical Sciences.2025; 13(4): 265.     CrossRef
• Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
  Ki Hoon Kwak, Chang Hee Jung
  Endocrinology and Metabolism.2025; 40(6): 879.     CrossRef
• Research Progress of GLP-1 Receptor Agonists in the Treatment of Alzheimer’s Disease
  琳娜 勾
  Advances in Clinical Medicine.2025; 15(12): 2047.     CrossRef

Citations

Citations to this article as recorded by  

• Trends in nephrology: kidney metabolism as a therapeutic target
  Jessica S Kleer, Markus M Rinschen
  Nephrology Dialysis Transplantation.2026; 41(2): 193.     CrossRef
• Renoprotective effect of dulaglutide in L-NAME-induced hypertensive nephropathy in rats: insight into the roles of PPAR-gamma and VEGF
  Nermeen Bastawy, Aliaa E. M. K. El-Mosallamy, Rabab Ahmed Rasheed, A. S. Sadek, R. T. Khattab, Esraa Ali, Randa A. Zaghloul, Wael B. A. Ghaly, Amy F. Boushra
  Hypertension Research.2026; 49(3): 816.     CrossRef
• Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
  Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
  Diabetes, Obesity and Metabolism.2026; 28(3): 1764.     CrossRef
• Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex
  Changyuan Yang, Petra Denig, Lynne Chepulis, Ryan G. Paul, Jung‐Im Shin, Ron T. Gansevoort, Priya Vart
  Diabetes, Obesity and Metabolism.2026; 28(3): 2265.     CrossRef
• GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications
  Areesha Moiz, Tetiana Zolotarova, Kristian B Filion, Mark J Eisenberg
  American Journal of Hypertension.2026; 39(5): 611.     CrossRef
• Diabetic kidney disease: integrating multi-omics insights, artificial intelligence, and novel therapeutics for precision medicine
  Tao Li, Kaili Chen, Yiting Sun, Linqi Zhang
  Frontiers in Genetics.2026;[Epub]     CrossRef
• Nobiletin Ameliorated the Development of Diabetic Kidney Disease via Modulating Ferroptosis and Epithelial–Mesenchymal Transition Involving Gut–Kidney Axis
  Tingting Zhao, Chuyun Zhao, Qian Xiang, Xi Zhang, Kin-Fong Hong, Peiyu Liu, Zhongyan Sun, Yadi Liu, Ruiting Huang, Yiran Li, Hio-Fai Cheong, Yuwei Wu, Yingqiu Mo, Yiduo Xu, Yingxi Zhao, Qiruo Huang, Ying Xie, Youhua Xu
  The American Journal of Chinese Medicine.2026; 54(01): 303.     CrossRef
• Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists
  Marios Spanakis, Agapi Fournaraki, Frantzeska Nimee, Christos Kontogiorgis, Emmanouil K. Symvoulakis
  Pharmaceuticals.2026; 19(2): 271.     CrossRef
• Diabetic kidney disease in northwest Ethiopia: Prevalence and determinants among adults with type 2 diabetes
  Workagegnehu Hailu, Tadesse Asmamaw Dejene, Markeshaw Tiruneh, Meseret Derbew Molla, Eshetie Melese Birru, Shitaye Alemu, Tadesse Awoke, Francesca D'Addio
  PLOS One.2026; 21(2): e0343210.     CrossRef
• The Role of Non-Coding RNAs in the Pathogenesis and Progression of Diabetic Kidney Disease
  Yinfeng Guo, Yonghao Feng, Henglan Wu, Huanqing Gao
  International Journal of Molecular Sciences.2026; 27(5): 2352.     CrossRef
• Association between cardiovascular-kidney-metabolic syndrome stages and risk of all-cause mortality in U.S. adults: a cross-sectional survey based on NHANES
  Yuanze Du, Wenxue Sun, Jiaqi Zhang, Jinfeng Wang, Kai Deng, Xiaowei Qiao, Jie Zhang, Xiaofang Zhang, Yueyuan Li, Xinyu Zhang, Xin Yang, Fangyu Cheng, Zongshuai Wang, Chunping Wang
  BMC Cardiovascular Disorders.2026;[Epub]     CrossRef
• Integrated discovery of SBLR876: a potent RAGE inhibitor mitigating AGE–RAGE–NF-κB-mediated cytotoxicity and inflammation in diabetic kidney disease
  Mesfer Mohammad AL Shahrani, Mohammad Abohassan, Ayed A. Dera, Sivakumar Vijayaraghavalu, Prasanna Rajagopalan
  Biochemical and Biophysical Research Communications.2026; 811: 153540.     CrossRef
• Glucagon-like peptide-1 receptor agonist and lupus nephritis in systemic lupus erythematosus with type 2 diabetes
  Muhammad Hanif, Jai S. Nagarajan, Ryan Murphy, Shiva P. Sah, Shuang Ye, Andras Perl, Cynthia C. Taub
  The American Journal of Medicine.2026; 139(6): 769.     CrossRef
• Impact of a structured nurse-delivered multi component SGLT2 inhibitor initiation and optimization pathway on kidney function and clinical outcomes in type 2 diabetes and chronic kidney disease: a real-world retrospective study
  Liang Huang, Muhui Yi
  BMC Nephrology.2026;[Epub]     CrossRef
• Інгібітори натрій-глюкозного котранспортера 2-го типу в контексті кардіоренально-метаболічної коморбідності. Частина 2: метаболомічні аспекти нефропротекції
  Vira V. Zlatkina, Andriy O. Nesen, Nadiia V. Demikhova
  Ukrainian Journal of Nephrology and Dialysis.2026; (1(89)): 94.     CrossRef
• Kidney angiopoietin-like protein 4 regulates fibrotic responses in diabetic kidney disease
  Swayam Prakash Srivastava, Ajan Vishnu Arora, Mariam Hamed, Adesh Urval, Aashika Dupati, Shangyang Xia, Shota Yoshida, Ken Inoki
  Frontiers in Pharmacology.2026;[Epub]     CrossRef
• Prediction model for rapid estimated glomerular filtration rate decline in type 2 diabetes mellitus
  Peng Huang, Xue-Qiong Qin, Qing Huang, Si-Dan Wang, Yuan-Yuan Wu, Xiu-Rong Huang, Xu Lin
  World Journal of Diabetes.2026;[Epub]     CrossRef
• Integrated analysis of the circRNA–miRNA–mRNA regulatory network underlying the therapeutic effects of Jinkui Shenqi Wan, a traditional Chinese medicine formula, in diabetic kidney disease: A network pharmacology and bioinformatics study
  Yao Xu, Qingying Tan, Tianxiao Hu, Yanxia Ren, Jiaqi Yao, Xiujing Wang, Peiwu Jiang
  Medicine.2026; 105(16): e48377.     CrossRef
• Fatty Kidney: The Interplay of Lipids and Diabetic Kidney Disease
  Zhiyue Zou, Pan Gao, Qian Yuan, Zhiwen Wang, Pengli Luo, Chun Zhang
  Biomedicines.2026; 14(4): 944.     CrossRef
• Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension
  Jun Sung Moon, Kyung-Ah Han, Jae Myung Yu, Jong Chul Won, Jun Goo Kang, Soojin Park, Cheol-Young Park
  Diabetes Research and Clinical Practice.2026; 236: 113272.     CrossRef
• Inflammation mediates the association of heavy metal exposures with kidney function: Evidence from a longitudinal study
  Jingtao Wu, Amujilite, Guohuan Yin, Ziyu Dong, Jing Xu, Qun Xu
  Ecotoxicology and Environmental Safety.2026; 316: 120174.     CrossRef
• From Single-target to System Remodeling：Combination Therapeutic Strategies for Metabolic Diseases
  Zhifu Xie, Jingya Li
  Bulletin of National Natural Science Foundation of China.2026; 40(2): 301.     CrossRef
• Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
  Dominik Kylies, Leonie Dreher, Ulrich O. Wenzel
  Current Hypertension Reports.2026;[Epub]     CrossRef
• Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulation
  Ying-Ru Chen, Zheng-Hong Jiang, Jui-Yi Chen, Vin-Cent Wu
  GeroScience.2026;[Epub]     CrossRef
• Protective effects of SGLT2 inhibitors and GLP-1 receptor agonists on infection-related implant failure following ankle fracture ORIF: A global big data analysis
  Mao Yi Yang, Li Wei Hung
  Journal of Orthopaedic Surgery.2026;[Epub]     CrossRef
• Defining the Roles of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Management of Chronic Kidney Disease in Adults with Type 2 Diabetes With or Without Overweight/Obesity: An International Delphi Consensus
  Yehuda Handelsman, Alice Y. Y. Cheng, Gian Paolo Fadini, Pam Kushner, Fabrice Bonnet, Paola Fioretto, Takashi Kadowaki, Naresh Kanumilli, Xavier Cos, Thomas Frese, Linong Ji, Peter Rossing
  Advances in Therapy.2026; 43(9): 3886.     CrossRef
• Inotodiol ameliorates oxidative stress and apoptosis by regulating PI3K/Akt/GSK-3β signaling pathways in diabetic nephropathy
  Lingling Tian, SiJie Zhang, Ziyang Ye, Jianbo Qing, Feng Wu, Qian Wang, Rongshan Li, Yafeng Li, Qi Duan
  Renal Failure.2026;[Epub]     CrossRef
• Personalizing Cardio-Kidney-Metabolic Therapy
  Qandeel H. Soomro, David M. Charytan
  Journal of the American Society of Nephrology.2026; 37(8): 1619.     CrossRef
• Molecular Pathways of Cardiometabolic Residual Risk in Type 2 Diabetes: Insulin Resistance, Metaflammation, and Liver–Kidney–Vascular Crosstalk
  Antonio Maria Labate, Elena Cimino, Laura Giacomelli, Stefano Ettori, Oladayo Adigun Oladeji, Barbara Agosti
  International Journal of Molecular Sciences.2026; 27(14): 6170.     CrossRef
• Revisiting Insulin Resistance in the Pathophysiology of Type 2 Diabetes Mellitus: A Multi-Organ Perspective
  Soo Lim, Seung-Hwan Lee, Robert H. Eckel
  Diabetes & Metabolism Journal.2026; 50(4): 641.     CrossRef
• Molecular and cellular mechanisms of GLP-1 receptor agonists and their emerging clinical applications
  Mateusz Kurowski, Katarzyna Rekiel, Aleksandra Marcinkowska, Oskar Ratajczyk, Piotr Urbanowicz, Stanisław Iwankiewicz, Wojciech Grzelczak, Zuzanna Kaz mierczak
  Medical Journal of Cell Biology.2026; 14(2): 40.     CrossRef
• Ozone-induced renal homeostasis disruption in diabetic mice: The role of Th17/Treg imbalance and drug intervention
  Ruru Meng, Jingge Cao, Shurui Wang, Donglei Wang, Shanshan Feng, Ruohui Chen, Caixia Guo, Min Zhang, Yanbo Li
  Journal of Hazardous Materials.2026; 515: 143029.     CrossRef
• Renal Replacement Therapy in Cardiovascular-Kidney-Metabolic Syndrome: Challenges for Dialytic Therapies and Kidney Transplantation
  Mahtab Mashayekhi, Jasjot Bhullar, Zohreh Gholizadeh Ghozloujeh, Sayna Norouzi, Khalil Pathan, Amir Abdipour
  Cardiorenal Medicine.2026; 16(1): 357.     CrossRef
• From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists
  Xue Tian, Xiaoying Ma, Enxue Song, Xilian Li, Wenlan Fu, Haiwei He, Zhiyuan Gao, Biao Gao
  Translational Research.2026; 296: 86.     CrossRef
• From Risk Determinants to Clinical Action
  Tazeen H. Jafar, Anqi Zhu, Oluwabunmi Ogungbe
  Clinical Journal of the American Society of Nephrology.2026;[Epub]     CrossRef
• Cardiometabolic Syndrome Part 2: Pharmacological Management, Public Health Strategies, and Future Direction
  Soo Lim, You-Cheol Hwang, Jang Won Son, Seung-Hwan Lee, Chang Hee Jung, Hyun-Jin Kim, Hyunjung Lim, Seong-Mi Park, Jang-Young Kim, Jong Chan Youn, Sung Kee Ryu, Sihoon Lee, Min-Jeong Shin, Sae Young Jae, Hun-Jun Park, Sang Min Park, Børge G Nordestgaard,
  CardioMetabolic Syndrome Journal.2026; 6(2): 193.     CrossRef
• Real-World Prescribing Patterns and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Empagliflozin-Sitagliptin-Metformin Fixed-Dose Combination Therapy
  Balaji T Naik, Shrimant Y, Debasish Patro, Suryakant Pankaj, Manoj Gaur, George Paulose, Rohan Kate, Dilip Gude, Ashish Patel, Sumit Sarkar, Aadil B Wasil, Utsa Basu, Ankit Chhabra, N Thyagarajan, Gurunath Chavan, Pradip Mate
  Cureus.2026;[Epub]     CrossRef
• Lifestyle Medicine as Co-Therapy During Incretin-Based Anti-Obesity Pharmacotherapy: Integrating Physical Activity, Nutrition, and Behavioral Strategies for Long-Term Success
  Marta Mallardo, Antonietta Messina, Vincenzo Monda, Marco La Marra, Antonietta Monda, Salvatore Allocca, Maria Casillo, Girolamo Di Maio, Pasquale Perrone, Aurora Daniele, Marcellino Monda, Giovanni Messina, Fiorenzo Moscatelli, Rita Polito
  Nutrients.2026; 18(17): 2748.     CrossRef
• Unveiling the molecular toxicity of plasticizers derived from microplastics (DMP and DEP) in diabetic kidney disease: integrative insights from network toxicology and multi-omics analysis
  Kaifeng Xie, Jiasheng Huang, Shiyun Ling, Xinyu Shi, Hesheng Li, Renfa Huang, Hanli Lin
  Frontiers in Immunology.2026;[Epub]     CrossRef
• Short-Term Comparative Effects Of Semaglutide, Either Alone Or In Conjunction With Canagliflozin, On Early Diabetic Kidney Disease
  Wang Long
  Pakistan Journal of Pharmaceutical Sciences.2026;[Epub]     CrossRef
• Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs
  Jun Hwa Hong, Kyung Wan Min, Chang Beom Lee, Parinya Chamnan, Thanitha Sirirak, Kiran Sony, Sarinya Sattanon, Hae Jin Kim, Sang-Yong Kim, Younghee Kim, Jung A Heo, Jae Min Cho, Jae Jin Nah, Mi Hee Park, Jae Hyeon Kim
  Diabetes & Metabolism Journal.2026; 50(5): 952.     CrossRef
• Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
  Ji Yoon Kim, Nam Hoon Kim
  Diabetes & Metabolism Journal.2026; 50(5): 844.     CrossRef
• Hypothalamic Inflammaging: A Central Driver of Type 2 Diabetes Mellitus and Metabolic Disease in Aging
  Sang Hee Lyoo, Ki Hun Kim, Ki Woo Kim
  Diabetes & Metabolism Journal.2026; 50(5): 863.     CrossRef
• Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes
  Francesco Martines, Pietro Salvago, Francesca Vaccaro, Davide Vaccaro, Ginevra Malta, Fabiana Plescia, Stella Cascioferro, Gianluca Lavanco, Fulvio Plescia
  Pharmacology Research & Perspectives.2026;[Epub]     CrossRef
• A hypoxia-derived seven-gene signature reflects immune remodeling in diabetic kidney disease: integrated transcriptomic analysis and experimental validation
  Yue Ji, Jiakun Zhang, Xi Guo, Yunming Xiao, Tieshan Wang, Yifei Zhang, Zhixun Guo, Yuqi Wu, Liangzhen You, Wei Jing Liu
  Diabetes Research and Clinical Practice.2026; 241: 113568.     CrossRef
• Dysregulation of the miR-4286 in diabetic kidney disease and its role in inflammatory response
  Jiayong Zhang, Qilin Tang, Mengmeng Pu, Lin Yan, Yijun Chen, Bin Wang
  Diabetology & Metabolic Syndrome.2026;[Epub]     CrossRef
• Beyond waste: arginine metabolism and ammonium detoxification in cardiovascular–renal–metabolic disease
  Lauren Peysakhova, Maria Chrysopoulou, Markus M. Rinschen
  Trends in Endocrinology & Metabolism.2026;[Epub]     CrossRef
• Special Issue “Molecular Therapeutics for Diabetes and Related Complications”
  Kota V. Ramana
  International Journal of Molecular Sciences.2025; 26(12): 5585.     CrossRef
• Targeting ion channel networks in diabetic kidney disease: from molecular crosstalk to precision therapeutics and clinical innovation
  Wenfeng Wang, Bi Ke, Chen Wang, Xiaojing Xiong, Xiuyuan Feng, Hua Yan
  Frontiers in Medicine.2025;[Epub]     CrossRef
• SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
  Aryan Gajjar, Arvind Kumar Raju, Amani Gajjar, Mythili Menon, Syed Asfand Yar Shah, Sourbha Dani, Andrew Weinberg
  Biomedicines.2025; 13(8): 1924.     CrossRef
• Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients—A systematic review and network meta‐analysis
  Peter Bramlage, Anjaly Vijayan, Treesa P. Varghese, Deepthy Melepurakkal Sadanandan, Stefanie Lanzinger, Carmen Ferrero Rodriguez
  Diabetes, Obesity and Metabolism.2025; 27(11): 6254.     CrossRef
• Type 2 Diabetes and the Multifaceted Gut-X Axes
  Hezixian Guo, Liyi Pan, Qiuyi Wu, Linhao Wang, Zongjian Huang, Jie Wang, Li Wang, Xiang Fang, Sashuang Dong, Yanhua Zhu, Zhenlin Liao
  Nutrients.2025; 17(16): 2708.     CrossRef
• Nutriomics and artificial intelligence nutrition obesity cohort (NAINOC): a design paper for a prospective cohort for nutrition and obesity research
  Minyoung Lee, Sungha Park, Soo-Hyun Park, Ho-Young Park, Yu Ra Lee, Min-Sun Kim, Miso Nam, Jangho Lee, Hyein Seo, Yong-ho Lee, Chan Joo Lee, Jae-Ho Park, Hye Hyun Yoo, Hyun-Jin Kim, Kyong-Oh Shin, Yoshikazu Uchida, Kyungho Park
  Clinical Hypertension.2025;[Epub]     CrossRef
• Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence
  Atia Arif, Sanu Lama, Bhavna Singla, Shivam Singla, Sunita Kumawat, Anusha Tharwani, Muhammad Usman, Hamna Khalid, Venkata Madusudana Rao Kanukollu, Osatohanmwen Ekomwereren, Shabir Khan
  Cureus.2025;[Epub]     CrossRef
• Integrating UHPLC-QE-MS and Bioinformatics with Experimental Validation Reveals MAPK/FOS-Mediated Podocyte Apoptosis as the Key Mechanism of Alpiniae oxyphyllae and Saposhnikovia divaricata in Treating Diabetic Kidney Disease
  Xian Wang, Lin Zhang, Rongxin Tang, Wenlong Zhang, Yiqiang Xie, Kai Li
  Pharmaceuticals.2025; 18(10): 1449.     CrossRef
• GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
  Mark E. Cooper, Daniël H. van Raalte
  Journal of Clinical Investigation.2025;[Epub]     CrossRef
• Short-Term Laboratory Outcomes of SGLT2 Inhibitor Use in Type 2 Diabetic Patients: A Retrospective Analysis
  Hamood AlSudais, Turky AlSulaiman, Badi A. Alotaibi, Abdulrahman Alshalani, Abdulaziz M. Almuqrin, Rehab B. Albakr, Jehad A. Aldali
  Journal of Clinical Medicine.2025; 14(22): 7985.     CrossRef
• Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i
  Yixin Zhu, Chenxi Lv, Hanqi Yang, Qian Lu, XuChen Wang, Yueqi Zhang, Maojuan Guo, Bo Yang
  Renal Failure.2025;[Epub]     CrossRef
• FGF4-FGFR1 signaling promotes podocyte survival and glomerular function to ameliorate diabetic kidney disease in male mice
  Jie Zhou, Shuxin Wang, Jiaxin Lou, Beibin Pan, Min Zhao, Qian Li, Jing Zhou, Yali Du, Shuodan Ding, Meiling Yu, Jingjing Zhou, Xinwei Chen, Lingwei Jin, Xinyi Wang, Yepeng Hu, Zhe Wang, Xiaokun Li, Chao Zheng, Jian Sun, Zhifeng Huang
  Nature Communications.2025;[Epub]     CrossRef
• Food‐Herb Dual‐Function in Astragali Radix‐Poria‐Rheum: Network Pharmacology and Database Mining for Diabetic Kidney Disease Mechanisms Exploration
  Meizi Wang, Weizhong Li, Qiong Cheng, Jiayu Sun, Cheng Cheng, Nana Wang, Ping Zhou, Min Zha, Yufeng Yang
  Food Science & Nutrition.2025;[Epub]     CrossRef
• Інгібітори натрій-глюкозного котранспортера 2-го типу в контексті кардіоренально-метаболічної коморбідності. Частина 1: основи патофізіології та ключові клінічні дослідження
  Vira V. Zlatkina, Andriy O. Nesen, Nadiia V. Demikhova
  Ukrainian Journal of Nephrology and Dialysis.2025; (4(88)): 88.     CrossRef
• Long-term efficacy of dapagliflozin combined with Bifidobacterium triple viable tablets on metabolic syndrome and gut microbiota in overweight/obese patients with type 2 diabetes
  Kunyi Li, Zhi Li, Lifeng Liu
  Endocrine Connections.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Semaglutide beyond weight loss: Mechanistic insights and functional paradoxes from the SEMALEAN study
  Shambo S. Samajdar, Shashank Joshi
  Diabetes, Obesity and Metabolism.2026; 28(1): 779.     CrossRef
• Tirzepatide and Obesity: A Narrative Review
  Arya Singh, Rahnuma Ahmad, Kona Chowdhury, Mahendra Narwaria, Mainul Haque
  Advances in Human Biology.2026; 16(2): 290.     CrossRef
• An expert narrative review on the brain-kidney axis in diabetic kidney disease: Mechanisms and therapeutic insights
  Zongrui Zhang, Rangzi Yi, Shihong Xiong, Yushu Zhang, Xuebin Cao, Wenqi Zhen, Yang Yang, Na Gong
  Diabetes Research and Clinical Practice.2026; 233: 113055.     CrossRef
• Impaired Brain Incretin and Gut Hormone Expression in Human Alcohol-Related Brain Damage: Opportunities for Therapeutic Targeting
  Suzanne M. de la Monte, Ming Tong, Rolf I. Carlson, Greg Sutherland
  Biomolecules.2026; 16(1): 99.     CrossRef
• Plasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities
  Houda Zoubiri, Wassila Saiah, Amel Otmane, Hamza Saidi, Mohamed Makrelouf, Samir Ait Abderrhmane, Ali El Mahdi Haddam, Elhadj-Ahmed Koceir
  International Journal of Molecular Sciences.2026; 27(3): 1218.     CrossRef
• The Enterolimbic Axis: Gut-Brain Affective Circuits at the Crossroad of Metabolism, Emotion, and Behavior
  Antonio Gasbarrini, Francesca Sofia Galli, Gianluca Ianiro, Francesca Ponziani, Emanuele Rinninella
  American Journal of Gastroenterology.2026; 121(8): 1819.     CrossRef
• Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity
  Andrijana Koceva, Andrej Janež, Tajda Pečko, Mojca Jensterle
  Nutrients.2026; 18(4): 677.     CrossRef
• National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
  HK Chopra, Ashwani Mehta, CK Ponde, Navin C Nanda, GS Wander, Abraham Oomman, Prafulla Kerkar, SN Routray, GP Ratnaparkhi, Prashant Advani, Rituparna Shinde, Rajeev Agarwal, Ajay Mahajan, Jay Shah, Gaurav Verma, Sanjay Mittal, Dorairaj Prabhakar, D Ramesh
  Journal of The Association of Physicians of India.2026; 74(2): e8.     CrossRef
• Polysaccharides from Acanthopanax senticosus (Rupr. et Maxim.) Harms: Molecular Messengers Linking the Traditional Efficacy of Fortifying the Spleen, Replenishing Qi, and Calming the Spirit to Gut-Immune Axis Regulation
  Bichun Hu, Deyong Zeng, Junli Liu, Weiping Wang, Shuaimin Hu, Weihong Lu
  Journal of Future Foods.2026;[Epub]     CrossRef
• Obestatin: canonical and unexpected functions
  Icia Santos-Zas, Uxia Gurriaran-Rodriguez, Tania Cid-Diaz, Saul Leal-Lopez, Felipe F. Casanueva, Yolanda Pazos-Randulfe, Jesus P. Camiña
  Reviews in Endocrine and Metabolic Disorders.2026; 27(2): 317.     CrossRef
• The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis
  Junjie Lin, Rongtao Yang, Jiacheng Zhuang, Wenbo Zhang, Qiang Tong, Jiahui Liu, Ye Kang, Yuan Yuan
  Journal of Ovarian Research.2026;[Epub]     CrossRef
• Hypothalamus-liver talks: whispers in the language of metabolism
  Vitor Ferreira, Iara Fernández-González, Jane Jose Vattathara, Amanda Rodríguez-Díaz, Paola Fernández-Sanmartín, Carlos Diéguez
  Reviews in Endocrine and Metabolic Disorders.2026; 27(3): 519.     CrossRef
• Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance
  Ruxandra Cristina Marin, Cosmin Mihai Vesa, Delia Mirela Tit, Andrei-Flavius Radu, Gabriela S. Bungau
  International Journal of Molecular Sciences.2026; 27(7): 2988.     CrossRef
• Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders
  Yun Kyung Cho, Chang Hee Jung
  Clinical and Molecular Hepatology.2026; 32(2): 464.     CrossRef
• Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis
  Mehmet Kanbay, Sama Mahmoud Abdel-Rahman, Mustafa Guldan, Lasin Ozbek, Nur I Genc, Ahmet B Ak, Adrian Covic, Hayri K Goren
  Clinical Kidney Journal.2026;[Epub]     CrossRef
• DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model
  Linda Sasset, Andrew D. Cameron, Carleigh Sussman, Luisa Rubinelli, Debnath Maji, Robert Miller, Andy Thompson, Delcora Campbell, Melanie R. Walker, Marek M. Drozdz, Rachel A. Liberatore
  Molecular Therapy Nucleic Acids.2026; 37(2): 102946.     CrossRef
• Causes and consequences of discontinuation of GLP1RAs or tirzepatide
  Antonio Ceriello, Francesco Prattichizzo, Abdul Raouf Mastan Sheik Abdullah, Rosalba La Grotta, Cesare Celeste Berra, Barbara McGowan, Alicia Jenkins, Neale Cohen, Michael Albrecht Nauck, Giuseppina Tiziana Russo
  Nature Reviews Endocrinology.2026; 22(9): 530.     CrossRef
• Sweet killers: Animal toxins that mimic glucoregulatory hormones
  Isabela Gobbo Ferreira, Beatriz de Cássia da Silva Jacob, Emilly Regina Ramos, Lorena de Oliveira Agati, Beatriz de Castro Vieira, Manuela Berto Pucca, Eloise Trostdorf Filardi, Eliane Candiani Arantes, Isadora Sousa de Oliveira
  Toxicon.2026; 281: 109181.     CrossRef
• Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension
  Benoit Aguado, Thomas Lacoste-Palasset, Grégoire Ruffenach, Fabrice Bauer, Laurent Savale, Marc Humbert, David Montani, Fabrice Antigny
  ERJ Open Research.2026; 12(3): 01479-2025.     CrossRef
• Altered hypothalamic functional connectivity in adolescents with severe obesity
  Allison L. B. Shapiro, Meghan E. Pauley, Jaime M. Moore, Lucy Hall, Nicholas Stence, Susan L. Johnson, Kristen J. Nadeau, Kathleen L. Keller, Barbara J. Rolls, Marc-Andre Cornier, Jason R. Tregellas
  International Journal of Obesity.2026; 50(8): 1818.     CrossRef
• Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance
  Raynier Zambrano-Villacres, Martín Campuzano-Donoso, Claudia Reytor-González, Gianluca Rossetti, Luigi Cobellis, Francesco Cobellis, Vincenzo Pilone, Daniel Simancas-Racines, Luigi Schiavo
  Nutrients.2026; 18(11): 1751.     CrossRef
• Circadian rhythms of gut microbiota modulate nocturnal hyperglycemia in type 2 diabetes: a comprehensive review on mechanisms and chrono-targeted interventions
  Hanchi Ying, Qi Wang, Qian He, Yibo Cao, Guangyao Wei, Zhiqiang Xiao, Xiaoting Luo
  Frontiers in Microbiology.2026;[Epub]     CrossRef
• Targeting the GLP-1 receptor pathways for dual management of obesity and depression
  Ruchi Keswani, Shvetank Bhatt
  Drug Discovery Today.2026; 31(4): 104727.     CrossRef
• Hypothalamic orexigenic and anorexigenic neuropeptides in the rotenone model of Parkinson’s disease
  Zsombor Márton, Bence Pytel, Dávid Kovács, Máté Szabó, Zsófia Havasi, Gergely Berta, József Farkas, László Ákos Kovács, Nóra Füredi, Viktória Kormos, Balázs Gaszner
  Scientific Reports.2026;[Epub]     CrossRef
• Direct effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: A systematic review and meta-analysis
  Zoe Lee Greenblatt, Atena Tork, Ivy Cruz, Erik D. Fausak, Huy-an Tran, Mahima Krovidy, Cecilia Giulivi
  Metabolism Open.2026; 31: 100484.     CrossRef
• Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review
  Jenyfer M Fuentes-Mendoza, Marcio J Concepción-Zavaleta, Luisa Graciela Dongo-Dueñas, Jose Mariano J Jara-Pianto, Jhosmar Angel Sierra-Martel, Claudio Aldahir Medina-Angulo, Horus Michael Virú-Flores, Jeny J Mendoza-Godoy, Francisca E Zavaleta-Gutiérrez,
  World Journal of Clinical Pediatrics.2026;[Epub]     CrossRef
• Design, synthesis, and biological activity of novel oxazole-based small molecule allosteric GLP-1R agonists
  Ruifeng Wang, Qing Liu, Chaoyu Lu, Ke Chen, Shuihua Liu, Liyuan Guo, Zhengmin Guo, Yunfeng Liu, Yi Zhang
  European Journal of Medicinal Chemistry.2026; 318: 119206.     CrossRef
• Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice
  Mika Sawada, Naoko Nakanishi, Masakazu Aihara, Kanako Ohkuma, Shoko Hamano, Yoshitaka Sakurai, Rie Sekine, Satoshi Usami, Toshimasa Yamauchi, Naoto Kubota
  Endocrinology, Diabetes & Metabolism.2026;[Epub]     CrossRef
• Hidden Malnutrition in the GLP-1 Era: Micronutrient Status, Protein Adequacy, and Lean Mass as Emerging Nutritional Considerations—A Narrative Review
  Tamara Sorić, Ana Sarić, Andrija Ivanišin, Mario Lovrić, Mirta Milić, Martina Matovinović, Marijana Matek Sarić
  Nutrients.2026; 18(17): 2757.     CrossRef
• Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia
  Konstantinos Prokopidis, Stefano Cacciatore, Stephen D. Anton, John A. Batsis
  Advances in Therapy.2026;[Epub]     CrossRef
• GLP-1 Receptor Agonists and Reproductive Health
  Florence Porterfield, Jennifer Mulligan, Katherine Salim, Olayemi Olubowale, Fatima Cody Stanford
  Endocrinology and Metabolism Clinics of North America.2026;[Epub]     CrossRef
• Anti-Obesity Effects of Artocarpus integer Stem Bark Extract via Appetite and Lipid Metabolism Modulation in Obese Rats
  Anton Bahtiar, Sekar Ayu Rabbani, Asfareni Rahmah, Sirithon Siriamornpun
  Applied Biosciences.2026; 5(3): 79.     CrossRef
• Transcriptome profiling of human hypothalamic agouti-related protein and proopiomelanocortin neurons regulating energy homeostasis
  Szabolcs Takács, Katalin Skrapits, Balázs Göcz, Éva Rumpler, Miklós Sárvári, Barbara Göblyös, Dalma Biri, Szilárd Póliska, Gergely Rácz, András Matolcsy, Erik Hrabovszky
  Nature Communications.2026;[Epub]     CrossRef
• Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials
  Elsayed S. Moubarak, Mohamed S. Elgendy, Omar Elkoumi, Ahmed A. Ibrahim, AlMothana Manasrah, Jamal Ahmad, Malak A. Hassan, Omar ElSayed Rageh, Abdelrahman Aly Mohamed, Amr Elzahaby, Mohamed Abuelazm
  Journal of Psychopharmacology.2026;[Epub]     CrossRef
• Assessing the quality and reliability of health information on GLP-1 receptor agonists on TikTok and Bilibili: a cross-sectional analysis of the public health infodemic
  Gang Peng, Chen Wang, Hong-Wei Zhang, Ting Xu, Jian-Zhong Di
  Therapeutic Advances in Endocrinology and Metabolism.2026;[Epub]     CrossRef
• Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
  Ji Yoon Kim, Nam Hoon Kim
  Diabetes & Metabolism Journal.2026; 50(5): 844.     CrossRef
• Hypothalamic Inflammaging: A Central Driver of Type 2 Diabetes Mellitus and Metabolic Disease in Aging
  Sang Hee Lyoo, Ki Hun Kim, Ki Woo Kim
  Diabetes & Metabolism Journal.2026; 50(5): 863.     CrossRef
• Neuroendocrine regulation of appetite and energy balance in metabolic disorders
  Mst. Mohona Khatun, Md. Nazmul Ahsan Sarker, Mohammad Shahangir Biswas, Munna Kumar Podder, Sabrina Akter
  IBRO Neuroscience Reports.2026; 21: 911.     CrossRef
• The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
  Ghinwa M. Barakat, Samer El Hajj Hassan, Hussein Issa, Wiam Ramadan
  Current Drug Therapy.2026; 21(5): 660.     CrossRef
• Beyond Weight Loss: Tolerability, Acceptability, and Patient-Centered Outcomes of GLP-1 Receptor Agonists in Polycystic Ovary Syndrome
  Urvah Tauseef, Farshi Farook, Vaishnavi J. Shetty, Edith Ramos-Ocola, Chandra Rupini Premkumar, Muhammad Zaryab Haider, Aashna Gandhi, Tunisha Shingala, Simardeep Singh, Muhammad Moiz Tahir, Sancia Mary Jerold Wilson, Kaaviyashri Saraboji, Jyoti Yadav, An
  Reproductive Medicine.2026; 7(4): 55.     CrossRef
• Hijacked Brain in Modern Obesity: Cue, Habit, Addiction, Emotion, and Restraint as Targets for Personalized Digital Therapy and Electroceuticals
  Taesung Lee, Seeun Park, Seokhyun Lee, Areum Hwangbo, HanGyeol Bae, Yumin Lee, Hyung Jin Choi
  Journal of Obesity & Metabolic Syndrome.2025; 34(3): 196.     CrossRef
• Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis
  Zixuan Li, Zhoubo Han, Rong Sun, Xiuping Xuan, Chenghu Huang
  Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 3611.     CrossRef
• The LEPR gene: A multifaceted regulator of energy homeostasis, obesity pathogenesis, and metabolic health
  Isar Sharma, Nishutosh, Kritika Bakshi, Ritu Mahajan, Nisha Kapoor
  Human Gene.2025; 46: 201486.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists Are Promising for the Treatment of Brain Diseases: an Outlook from the Perspective of Integrative Physiology
  N. V. Gulyaeva
  Journal of Evolutionary Biochemistry and Physiology.2025; 61(5): 1326.     CrossRef
• Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes
  Isabel Krug, An Binh Dang, Jade Portingale, Yakun Li, Ying Qing Won
  Nutrients.2025; 17(23): 3735.     CrossRef
• A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
  E. A. Troshina, M. B. Antsiferov, A. S. Ametov, G. R. Galstyan, T. N. Markova, T. I. Romantsova, N. V. Mazurina, O. M. Koteshkova
  Problems of Endocrinology.2025; 71(5): 19.     CrossRef

Citations

Citations to this article as recorded by  

• Implications of Glucagon-like Peptide-1 Receptor Agonists on Thyroid Function and Thyroid Nodules: A Drug Target Mendelian Randomization and Cohort Study
  Zhijun Zhang, Jingyun Yang, Ling Gao
  Endocrine Practice.2026; 32(1): 60.     CrossRef
• Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer
  Stefano Iuliano, Maria Mirabelli, Stefania Giuliano, Antonio Brunetti
  Current Opinion in Oncology.2026; 38(1): 1.     CrossRef
• Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
  Tina Vilsbøll, Michael Stellfeld, Vanita R. Aroda, Sune Dandanell, Jens‐Peter David, Ceyda T. P. Kristiansen, Søren Rasmussen, Fiona L. Roberts, Laszlo Hegedüs
  Diabetes, Obesity and Metabolism.2026; 28(2): 1499.     CrossRef
• Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
  Setor K. Kunutsor, Samuel Seidu
  Drugs.2026; 86(1): 11.     CrossRef
• Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer
  Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert
  Clinical Endocrinology.2026; 104(5): 507.     CrossRef
• Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis
  Sarina Ailawadi, Jennifer E. Murphy, Michael H. Storandt, Amit Mahipal
  Cancers.2026; 18(2): 179.     CrossRef
• Mechanisms in diabetes mellitus: Relationships to metabolism and/or neoplasia
  John A. D'Elia, Bijan Roshan, Larry A. Weinrauch
  Journal of Diabetes and its Complications.2026; 40(4): 109289.     CrossRef
• Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis
  Yousef A. Ateiwi, Rahil Mahmood, Hon Jen Wong, Chen Ee Low, Chun En Yau, Ainsley Ryan Yan Bin Lee, Pei Chia Eng, Matilda Lee, Mark Y. Chan, Ching-Hui Sia
  Diabetes Research and Clinical Practice.2026; 234: 113158.     CrossRef
• Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE)
  Antonio Facciorusso, Edoardo G Giannini, Matteo Tacelli, Alberto Zanetto, Cristiano Spada, Ivo Boskoski, Manuele Furnari, Grazia Pennisi, Gabriele Capurso, Alessandro Vitello, Giovanni Marasco, Giovanni Sarnelli, Luca Frulloni, Marcello Maida
  Digestive and Liver Disease.2026; 58(6): 737.     CrossRef
• Anti-diabetic Drugs and Cancer: Integrated Mechanisms of Tumor Suppression and Clinical Translation
  Mahya Asadalizadeh, Mohammad Kazem Molavi Rahbar, Tabassom Mahmoudie, Mahshid Abbasi, Mitra Akbari, Davoud Shakiba, Aida Mohammadiun Shabestari, Meysam Ebrahimifar
  Indian Journal of Clinical Biochemistry.2026;[Epub]     CrossRef
• Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis
  Gaetano Lauri, Paolo Giorgio Arcidiacono, Antonio Facciorusso, Gabriele Capurso, Matteo Tacelli
  Pancreatology.2026; 26(6): 854.     CrossRef
• GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
  Klaudia Nowak, Krzysztof Łupina, Aleksandra Kalisz, Łucja Ilkiewicz, Jakub Janczura
  Current Pharmacology Reports.2026;[Epub]     CrossRef
• Optimizing glycemic control in oncology patients with diabetes mellitus
  S. Anandkumar, P. Shobana, B. Tharun, M. Vijayasakthi, R. Kaviya, P. Ajitkumar
  Journal of Oncology Pharmacy Practice.2026;[Epub]     CrossRef
• Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis
  Dong Lei, Jin-H Wu, Xi-H Zeng, Ran Xu, Shun-S Zheng, Xue-J Zhu, Jian-A Yang
  Urologic Oncology: Seminars and Original Investigations.2026; 44(9): 182.     CrossRef
• Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study
  Byeong Geun Song, Tae-Se Kim, Bong Seong Kim, Kyungdo Han, Byung-Hoon Min
  Diabetes & Metabolism.2026; 52(4): 101776.     CrossRef
• GLP‐1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study
  Jisu Park, Ju Hwan Kim, Yoon Seob Kim, Gyeongmin Lim, Hong Ji Song, Sang Youl Rhee, Seonghoon Hwang, Daeun Cho, Minyoung Kim, Bo‐Yeon Kim, Chang Won Jeong, Dae‐Yeon Kim, Hang A Park, Min‐Ho Kim, Seong Hwan Kim, Won‐Woo Seo, Woo Jin Kim, Young Sung Suh, Ra
  Diabetes, Obesity and Metabolism.2026; 28(9): 8649.     CrossRef
• Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis
  Ejike Daniel Eze, Leopold Ntakirutimana, Swase Dominic Terkimbi, Muluken Walle, Abdullahi Hussein Umar, Diresibachew Haile Wondimu, Makinde Vincent Olubiyi, Onyinye Cynthia Okeke, Olufunke Onaadepo, Jimoh Abdulazeez, David Chibuike Ikwuka, Elemi John Ani,
  Frontiers in Oncology.2026;[Epub]     CrossRef
• Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-Analysis
  Isha Lalani, Reynaldo Nambayan, Chantelle Carbonell, Yibing Ruan, Dylan E. O’Sullivan, Igor Stukalin, Robert J. Hilsden, Darren R. Brenner
  Cancer Control.2026;[Epub]     CrossRef
• GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
  Giovanni Antonio Silverii, Christian Marinelli, Costanza Bettarini, Gloria Giovanna Del Vescovo, Matteo Monami, Edoardo Mannucci
  Diabetes, Obesity and Metabolism.2025; 27(8): 4454.     CrossRef
• Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules
  Sanjana Balachandra, Rohma Syed, Zhixing Song, Julia Kasmirski, Andrea Gillis, Jessica Fazendin, Brenessa Lindeman, Herbert Chen
  Journal of Surgical Research.2025; 312: 104.     CrossRef
• Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
  Jung A Kim, Hye Jin Yoo
  Diabetes & Metabolism Journal.2025; 49(4): 525.     CrossRef
• Association between Cancer and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review of Retrospective Cohort Studies
  Hyun Jin Park, Si Yoon Lee
  Research in Clinical Pharmacy.2025; 3(1): 28.     CrossRef
• GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study
  Omar Faour, Moheb Boktor, Hanford Yau, Mustafa Kinaan, Ishak A Mansi
  American Journal of Medicine Open.2025; 14: 100114.     CrossRef
• Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates
  Sabina Semiz
  Health Sciences Review.2025; 17: 100244.     CrossRef
• GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
  Estefania Valencia-Rincón, Rajani Rai, Vishal Chandra, Elizabeth A. Wellberg
  Journal of Clinical Investigation.2025;[Epub]     CrossRef
• GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways
  Daniela Lucente, Stefania Bellino, Anna La Salvia
  Genes.2025; 16(11): 1352.     CrossRef
• Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
  Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
  Diabetes & Metabolism Journal.2025; 49(6): 1331.     CrossRef

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between Asian and non-Asian populations. We reviewed available data on GLP-1RAs, focusing on Korean patients, to better understand their risk/benefit profile and help inform local clinical practice. Control of postprandial hyperglycemia is important in Asians in whom the prevalence of post-challenge hyperglycemia is higher (vs. non-Asians). The weight lowering effects of GLP-1RAs are becoming more salient as the prevalence of overweight and obesity among Korean patients increases. The higher rate of gastrointestinal adverse events amongst Asian patients in clinical trials may be caused by higher drug exposure due to the lower body mass index of the participants (vs. non-Asian studies). Data on the durability of weight loss, clinically important health outcomes, safety and optimal dosing in Korean patients are lacking. Use of GLP-1RAs is appropriate in several patient groups, including patients whose HbA1c is uncontrolled, especially if this is due to postprandial glucose excursions and patients who are overweight or obese due to dietary problems (e.g., appetite control). The potential for gastrointestinal adverse events should be explained to patients at treatment initiation to facilitate the promotion of better compliance.

Citations

Citations to this article as recorded by  

• Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
  Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
  Diabetes & Metabolism Journal.2024; 48(3): 418.     CrossRef
• Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
  Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
• Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef